The use of botulinum neurotoxin type A (BoNTA) in urology
Authors:
- 6 March 2008
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 115 (4) , 593-605
Abstract
The use of Botulinum neurotoxin type A (BoNT/A) in the lower urinary tract was pioneered as early as 20 years ago with injections into the urethral sphincter reducing bladder voiding pressures, urethral pressures, and post-void residual urine. Over the past 9 years, the use of BoNT/A has revolutionised the treatment of intractable symptoms associated with the neurogenic or idiopathic overactive bladder, both in adults and children. The duration of clinical improvement is 6–11 months, is accompanied by significant amelioration of patients’ quality of life and repeat bladder treatments appear to have sustained effects. Despite evidence for an effect on the afferent pathways, its mode of action in the human bladder remains largely unknown. The use of BoNT/A has also expanded into the painful bladder syndrome and in benign prostatic diseases, with promising preliminary results.Keywords
This publication has 104 references indexed in Scilit:
- Botulinum A Toxin Intravesical Injections in the Treatment of Painful Bladder Syndrome: A Pilot StudyEuropean Urology, 2006
- Evaluation of Short Term Clinical Effects and Presumptive Mechanism of Botulinum Toxin Type A as a Treatment Modality of Benign Prostatic HyperplasiaYonsei Medical Journal, 2006
- A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivityBJU International, 2005
- BLADDER Aδ AFFERENT NERVE ACTIVITY IN NORMAL CATS AND CATS WITH FELINE INTERSTITIAL CYSTITISJournal of Urology, 2005
- INHIBITORY EFFECT OF INTRAVESICALLY APPLIED BOTULINUM TOXIN A IN CHRONIC BLADDER INFLAMMATIONJournal of Urology, 2005
- Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injuryNeurochemistry International, 2004
- Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan‐neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatmentBJU International, 2004
- Electrical Characteristics of Suburothelial Cells Isolated From the Human BladderJournal of Urology, 2004
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- AUGMENTED STRETCH ACTIVATED ADENOSINE TRIPHOSPHATE RELEASE FROM BLADDER UROEPITHELIAL CELLS IN PATIENTS WITH INTERSTITIAL CYSTITISJournal of Urology, 2001